Physician profile
John Eunjin Kwon
NPI 1922850437
$3,427.71
in general payments reported to CMS, 2019-2025
29 companies · $1,211 in 2025
The $1,211 reported for 2025 was more than what 87% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,217 · 2025: $1,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,427.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $591.21 | 2024-2025 | Farxiga, Airsupra |
| Abbvie INC. | $491.93 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $318.72 | 2024-2025 | |
| Novo Nordisk INC | $314.96 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $300.86 | 2024-2025 | Evenity, Otezla, Repatha |
| Astellas Pharma US INC | $154.73 | 2024-2025 | Veozah |
| Aimmune Therapeutics, INC. | $132.31 | 2024-2025 | Zenpep |
| Esperion Therapeutics, INC. | $131.17 | 2024 | Nexletol, Nexlizet |
| Regeneron Healthcare Solutions, INC. | $124.74 | 2024 | |
| Phathom Pharmaceuticals, INC. | $116.88 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $113.00 | 2024 | Zeposia |
| Lilly USA, LLC | $110.01 | 2024-2025 | Mounjaro, Kisunla |
| Gilead Sciences, INC. | $69.21 | 2024-2025 | |
| Corcept Therapeutics | $57.68 | 2024-2025 | Korlym |
| Ardelyx, INC. | $42.47 | 2024-2025 | Ibsrela |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.93 | 2024 | |
| Dexcom, INC. | $36.87 | 2024-2025 | Dexcom G6 Transmitter |
| Scilex Pharmaceuticals INC. | $32.63 | 2024-2025 | |
| Scpharmaceuticals INC. | $30.72 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $29.62 | 2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $28.76 | 2025 | Zoryve |
| Vertex Pharmaceuticals Incorporated | $27.38 | 2025 | |
| Digestive Care, INC. | $22.22 | 2024 | Pertzye |
| Xeris Pharmaceuticals, INC. | $21.25 | 2025 | Keveyis |
| Sanofi Pasteur INC. | $20.00 | 2025 | |
| Exact Sciences Corporation | $18.70 | 2024 | Cologuard Collection Kit |
| Pfizer INC. | $18.32 | 2025 | |
| Alvogen INC | $17.65 | 2025 | Teriparatide |
| Merck Sharp & Dohme LLC | $13.78 | 2025 | Gardasil 9, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kwon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.